文献速递胸部肿瘤放疗放疗物理与技术

立体定向体部放疗治疗超中央型肺部恶性肿瘤:更新系统综述与荟萃分析

Stereotactic body radiation therapy for ultra-central lung malignancies: an updated systematic review and meta-analysis.
PubMed 文献 · Radiat Oncol · 2026-05-11

汇总1年、2年局部控制率分别为93%和84%,1年、2年总生存率分别为81%和58%,≥3级和5级治疗相关副作用分别为9%和2%。BED10与局部控制及总生存呈正相关,PTV体积与两者呈负相关。

要点

  • SBRT治疗超中央型肺部肿瘤的汇总1年局部控制率为93%,2年为84%。
  • 汇总≥3级治疗相关副作用为9%,5级为2%,总体安全性可接受但需警惕。
  • BED10越高、PTV体积越小,局部控制与总生存越好。

核心结论

  • SBRT治疗超中央型肺部恶性肿瘤可获得较好的局部控制率,且相对安全,但5级副作用仍需警惕。

研究设计与样本

  • 采用随机效应模型分析临床结局,并用荟萃回归分析各协变量对局部控制和总生存的影响。

主要发现

  • 汇总1年局部控制率为93%(95%CI:88-96%),2年局部控制率为84%(95%CI:77-89%)。
  • 汇总1年总生存率为81%(95%CI:77-85%),2年总生存率为58%(95%CI:52-64%)。
  • 汇总≥3级治疗相关副作用发生率为9%(95%CI:6-14%),5级为2%(95%CI:1-5%)。
  • 荟萃回归显示BED10与1年局部控制(P=0.001)和2年局部控制(P<0.001)呈显著正相关。
  • 荟萃回归显示PTV体积与1年局部控制(P=0.048)和2年局部控制(P=0.030)呈显著负相关。

关键数值与推荐

  • 超中央型肺部恶性肿瘤SBRT的汇总1年局部控制率为93%(95%CI:88-96%),2年为84%(95%CI:77-89%)。
  • 汇总1年总生存率为81%(95%CI:77-85%),2年为58%(95%CI:52-64%)。
  • 汇总≥3级治疗相关副作用发生率为9%(95%CI:6-14%),5级为2%(95%CI:1-5%)。

临床怎么用

  • 对于超中央型肺部恶性肿瘤,SBRT可作为获得较好局部控制且相对安全的治疗选择,但需对5级副作用保持警惕。
  • 在制定SBRT计划时,可考虑提高BED10并尽量缩小PTV体积,以改善局部控制和总生存。

局限性

  • 结论基于回顾性研究为主的系统综述与荟萃分析,仍需进一步前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Stereotactic body radiotherapy (SBRT) is a highly effective and well-tolerated treatment modality for peripherally located early-stage non-small cell lung cancer as well as pulmonary metastases. However, its feasibility and safety remain uncertain in patients with ultra-central (UC) lung tumors. This study aims to evaluate the efficacy and safety of SBRT in the management of UC lung malignancies. METHODS: A systematic review of the available literature was conducted in accordance with the PRISMA guidelines, incorporating studies that reported both treatment-related side effects and therapeutic efficacy associated with SBRT for UC lung malignancies. Patient characteristics, prescription doses, local control (LC), overall survival (OS), and side effects information were extracted. Clinical outcomes were analyzed using the random-effects model. Meta-regression was conducted to determine the effect of various covariates on LC and OS outcomes. RESULTS: Twenty-three articles with a total of 1,105 patients were included. Pooled 1- and 2-year LC rates were 93% (95% CI: 88-96%) and 84% (95% CI: 77-89%), respectively. Meta-regression demonstrated a significantly positive association between BED10 and 1- and 2-year LC rates (P = 0.001, P < 0.001, respectively), and a significantly negative association between PTV volume and 1- and 2-year LC (P = 0.048, P = 0.030, respectively). Pooled 1- and 2-year OS rates were 81% (95% CI: 77-85%) and 58% (95% CI: 52-64%), respectively. Meta-regression revealed a significantly positive association between BED10 and 1- and 2-year OS rates (P = 0.025, P = 0.002, respectively), and a significantly negative association between PTV volume and 1- and 2-year OS (P = 0.031, P < 0.001, respectively). The pooled rates of grade ≥ 3 and grade 5 treatment-related side effects were 9% (95% CI: 6-14%) and 2% (95% CI: 1-5%), respectively. CONCLUSION: This meta-analysis demonstrates that SBRT achieves favorable LC rates and is a relatively safe treatment for UC lung malignancies. Although the pooled rate of grade 5 side effects, at 2%, was within an acceptable range, vigilance remains essential. Further prospective research is warranted to verify our conclusions.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zeng H, Wang X, Bai H, et al. Stereotactic body radiation therapy for ultra-central lung malignancies: an updated systematic review and meta-analysis. Radiat Oncol. 2026. PMID: 42116164. doi:10.1186/s13014-026-02854-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。